Zacks: Analysts Expect Illumina, Inc. (ILMN) Will Post Quarterly Sales of $735.16 Million
Analysts expect that Illumina, Inc. (NASDAQ:ILMN) will post $735.16 million in sales for the current quarter, according to Zacks Investment Research. Seven analysts have provided estimates for Illumina’s earnings, with the highest sales estimate coming in at $741.30 million and the lowest estimate coming in at $728.41 million. Illumina reported sales of $619.35 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 18.7%. The firm is scheduled to announce its next quarterly earnings report on Tuesday, January 30th.
On average, analysts expect that Illumina will report full-year sales of $735.16 million for the current financial year, with estimates ranging from $2.70 billion to $2.72 billion. For the next fiscal year, analysts expect that the company will post sales of $3.06 billion per share, with estimates ranging from $2.94 billion to $3.19 billion. Zacks’ sales calculations are a mean average based on a survey of research analysts that follow Illumina.
Illumina (NASDAQ:ILMN) last announced its earnings results on Tuesday, October 24th. The life sciences company reported $1.11 EPS for the quarter, topping the consensus estimate of $0.99 by $0.12. The business had revenue of $714.00 million for the quarter, compared to the consensus estimate of $692.77 million. Illumina had a return on equity of 19.42% and a net margin of 30.34%. Illumina’s revenue was up 17.6% compared to the same quarter last year. During the same period in the previous year, the business earned $0.97 EPS.
Shares of Illumina (NASDAQ:ILMN) traded up $5.70 on Tuesday, hitting $216.55. The stock had a trading volume of 1,485,034 shares, compared to its average volume of 953,482. The firm has a market cap of $31,324.30, a P/E ratio of 62.73, a P/E/G ratio of 3.54 and a beta of 0.79. The company has a quick ratio of 3.73, a current ratio of 4.22 and a debt-to-equity ratio of 0.41. Illumina has a fifty-two week low of $126.18 and a fifty-two week high of $230.72.
In related news, SVP Charles Dadswell sold 145 shares of the business’s stock in a transaction that occurred on Tuesday, October 3rd. The shares were sold at an average price of $202.23, for a total value of $29,323.35. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Jay T. Flatley sold 20,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 10th. The stock was sold at an average price of $203.27, for a total transaction of $4,065,400.00. The disclosure for this sale can be found here. Insiders sold a total of 136,421 shares of company stock valued at $28,489,101 in the last 90 days. 0.89% of the stock is currently owned by corporate insiders.
Several institutional investors have recently modified their holdings of the business. Vanguard Group Inc. raised its position in shares of Illumina by 2.6% during the 2nd quarter. Vanguard Group Inc. now owns 9,904,340 shares of the life sciences company’s stock valued at $1,718,601,000 after acquiring an additional 255,498 shares during the last quarter. Ameriprise Financial Inc. raised its position in shares of Illumina by 3.1% during the 3rd quarter. Ameriprise Financial Inc. now owns 2,512,167 shares of the life sciences company’s stock valued at $500,416,000 after acquiring an additional 76,452 shares during the last quarter. Capital World Investors raised its position in shares of Illumina by 23.8% during the 2nd quarter. Capital World Investors now owns 2,135,000 shares of the life sciences company’s stock valued at $370,465,000 after acquiring an additional 410,000 shares during the last quarter. TIAA CREF Investment Management LLC raised its position in shares of Illumina by 55.6% during the 2nd quarter. TIAA CREF Investment Management LLC now owns 1,475,669 shares of the life sciences company’s stock valued at $256,058,000 after acquiring an additional 527,548 shares during the last quarter. Finally, Winslow Capital Management LLC bought a new stake in shares of Illumina during the 2nd quarter valued at $211,584,000. Institutional investors own 91.75% of the company’s stock.
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.